News

In a case study published in the International Journal of Cardiology, a team of researchers from China reported the case of a 23-year-old woman with the absence of a right pulmonary artery and patent ductus arterioles who developed severe pulmonary hypertension. The researchers found that the use of …

Patients with systemic sclerosis (SSc) are at an increased risk for mortality due to concurrent pulmonary hypertension or interstitial lung disease. While pulmonary hypertension results in right-sided heart failure, interstitial lung disease results in extensive lung fibrosis. It may be possible to test for lung scarring using high resolution computed…

Representatives from Bayer HealthCare Pharmaceuticals presented findings at the American Thoracic Society’s (ATS) 2015 International Conference that suggest pulmonary hypertension is more prevalent in patients with pulmonary embolisms than was previously thought. Although the rate may be at least twice as high as previously identified, many patients do not undergo the…

Celsion Corporation, an oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies, recently announced an abstract publication in the Journal of Controlled Release. The abstract summarizes results from a preclinical trial which confirmed the effective…

In a recent study entitled “An excellent result of surgical treatment in patients with severe pulmonary arterial hypertension following mitral valve disease,” authors analyzed recent outcomes and mortality rates for patients with pulmonary arterial hypertension who underwent mitral valve surgery. They observed a significant decrease in the number of deaths…

Bayer HealthCare will deliver six presentations at the ongoing American Thoracic Society (ATS) International Conference in Denver, Colorado. Five posters and one oral presentation will describe data concerning treatment of patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). “At the American Thoracic Society…

Insmed Incorporated, a biopharmaceutical company dedicated to improving the lives of patients battling rare lung diseases by developing orphan treatments recently announced that during the 2015 Annual Internation Conference of the American Thoracic Society (ATS) it will present three ARIKAYCE™ abstracts and three INS1009 abstracts. The conference will place…

Representatives from Actelion Pharmaceuticals Ltd will be presenting data from its Phase III GRIPHON and SERAPHIN studies at the American Thoracic Society (ATS) Conference 2015, held in Denver, Colorado. GRIPHON focused on the investigational drug selexipag (Uptravi®), while SERAPHIN focused on macitentan (Opsumit®). Both were used for patients with pulmonary…

Patricia Middings of Chester, N.J., is the winner of “Breathless Moments,” a photo contest launched by Bayer in order to raise awareness for chronic thromboembolic pulmonary hypertension (CTEPH). The idea of the challenge was to portray inspirational moments, events or sights that leave someone breathless. Contest judges Trace Cluck,…

The National Heart, Lung and Blood Institute has awarded a grant to two investigators from the Children’s Hospital of Philadelphia (CHOP) for their work creating an informatics registry for pediatric patients who suffer from pulmonary hypertension (PH). The institute from the National Institutes of Health (NIH)…

Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company, recently announced the formation of a Scientific Advisory Board (SAB) for its INOpulse technology that includes internationally recognized experts in the field of pulmonary hypertension (PH). The SAB will work closely with Bellerophon’s medical team while the firm prepares to further the advancement of its proprietary inhaled…

Specialty pharmaceutical company SteadyMed Ltd. has filled an application requesting orphan drug designation for its lead medical product, an investigational therapy to treat pulmonary arterial hypertension (PAH) called Trevyent. The application has been acknowledged by the U.S. Food and Drug Administration (FDA) and…